Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
Rabobank investeert 3 miljoen in ALS Investment Fund
nov 2017 | Neuro-musculair
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen